Eli Lilly (LLY): FY25 Q2 earnings call, Aug 7, 2025

Thu, Aug 7Earnings callSpeaker-labelled transcriptEli Lilly

No Kalshi or Polymarket word markets were listed for Eli Lilly’s Aug 7, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

9 matches for “Vial”; 4 quoted, at least 25 words apart.

David A. Rickscompanyprepared

…and SLL. And we launched the 2 highest doses of Zepbound in vials in the United States. We announced and closed the acquisition of SiteOne…

Lucas E. Montarcecompanyprepared

…total patients taking Zepbound. We recently launched the 12.5- and 15-milligram single-use vials in LillyDirect. All doses of Zepbound are not available in the vial…

Ilya Yuffacompanyqa

…you assume looking at the self-pay market that what we're seeing in vial performance and overall market is continuing to grow at rapid pace. We're…

Ilya Yuffacompanyqa

…that we've seen in Q2, we've generated over 1 million TRx in vial in Q2. And we recently launched last week, the highest doses of…

Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-08-07:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-08-07:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP